Adverse Cutaneous Reactions to Hydroxychloroquine A Dermatomyositis Than in Patients With Cutaneous Lup

Archives of Dermatology

138, 1231-3; discussion 1233

DOI: 10.1001/archderm.138.9.1231

Citation Report

#	Article	IF	Citations
1	Current Awareness: Pharmacoepidemiology and Drug Safety. Pharmacoepidemiology and Drug Safety, 2003, 12, 253-268.	0.9	0
2	Uso de los antimalÃ¡ricos en dermatologÃa. Piel, 2003, 18, 515-518.	0.0	2
3	Antimalarial lichenoid tissue reactions in patients with pre-existing lupus erythematosus. Lupus, 2004, 13, 473-477.	0.8	15
4	Skin manifestations of systemic autoimmune connective tissue disease: diagnostics and therapeutics. Best Practice and Research in Clinical Rheumatology, 2004, 18, 429-462.	1.4	54
6	Antiprotozoal drugs. Side Effects of Drugs Annual, 2004, , 289-302.	0.6	0
8	Optimal Use of Antimalarials in Treating Cutaneous Lupus Erythematosus. American Journal of Clinical Dermatology, 2005, 6, 1-11.	3.3	37
9	Management of Cutaneous Dermatomyositis. American Journal of Clinical Dermatology, 2006, 7, 341-351.	3.3	41
10	Dermatomyositis. Clinics in Dermatology, 2006, 24, 363-373.	0.8	194
12	Successful treatment of cutaneous lesions in juvenile dermatomyositis with high-dose intravenous immunoglobulin. British Journal of Dermatology, 2007, 156, 1390-1391.	1.4	10
13	New concepts in antimalarial use and mode of action in dermatology. Dermatologic Therapy, 2007, 20, 160-174.	0.8	234
14	Immunomodulatory treatment for dermatomyositis. Current Allergy and Asthma Reports, 2008, 8, 348-353.	2.4	9
15	The treatment and prognosis of dermatomyositis: An updated review. Journal of the American Academy of Dermatology, 2008, 59, 99-112.	0.6	102
16	Activity of certain drugs in inducing of inflammatory myopathies with cutaneous manifestations. Expert Opinion on Drug Safety, 2008, 7, 421-433.	1.0	24
17	Dermatomiosite. Anais Brasileiros De Dermatologia, 2008, 83, 247-259.	0.5	8
19	Cutaneous Manifestations of Dermatomyositis and Their Management. Current Rheumatology Reports, 2010, 12, 192-197.	2.1	49
20	The lichenoid reaction pattern (â€¨interface dermatitisâ€™). , 2010, , 35-70.e41.		14
21	Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. Journal of Rheumatology, 2010, 37, 1953-1961.	1.0	90
22	Juvenile-Onset Clinically Amyopathic Dermatomyositis. Paediatric Drugs, 2010, 12, 23-34.	1.3	26

#	Article	IF	Citations
23	JUVENILE DERMATOMYOSITIS. , 2011, , 375-413.		16
24	Dermatomiositis. Piel, 2011, 26, 330-340.	0.0	1
25	Antimalarial cutaneous side effects: a study in 209 users. Cutaneous and Ocular Toxicology, 2011, 30, 45-49.	0.5	38
26	Current management of dermatomyositis. International Journal of Clinical Rheumatology, 2012, 7, 197-215.	0.3	2
27	Management of cutaneous dermatomyositis. Dermatologic Therapy, 2012, 25, 112-134.	0.8	26
28	Cutaneous Dermatomyositis: An Updated Review of Treatment Options and Internal Associations. American Journal of Clinical Dermatology, 2013, 14, 291-313.	3.3	61
31	Antimalarials in Dermatology: Mechanism of Action, Indications, and Side Effects. Actas Dermo-sifiliogrÃ¡ficas, 2014, 105, 243-252.	0.2	18
32	Innate Immune-Response Mechanisms in Dermatomyositis: An Update on Pathogenesis, Diagnosis and Treatment. Drugs, 2014, 74, 981-998.	4.9	29
33	Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests. Dermatology, 2015, 231, 353-359.	0.9	27
34	Chloroquine and hydroxychloroquine. , 2016, , 253-267.		3
35	The skin in autoimmune diseasesâ€"Unmet needs. Autoimmunity Reviews, 2016, 15, 948-954.	2.5	17
36	Juvenile Dermatomyositis. , 2016, , 351-383.e18.		22
37	Corticosteroids in Myositis and Scleroderma. Rheumatic Disease Clinics of North America, 2016, 42, 103-118.	0.8	13
38	Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases. Lupus, 2017, 26, 1304-1308.	0.8	62
39	The systemic management of cutaneous dermatomyositis: Results of a stepwise strategy. International Journal of Women's Dermatology, 2017, 3, 189-194.	1.1	34
40	How I treat idiopathic patients with inflammatory myopathies in the clinical practice. Autoimmunity Reviews, 2017, 16, 999-1007.	2.5	22
41	Dermatomyositis: Current concepts. Clinics in Dermatology, 2018, 36, 450-458.	0.8	56
42	Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: A case report and review of the published work. Journal of Dermatology, 2018, 45, 344-348.	0.6	18

#	Article	IF	Citations
43	Pruritus in Autoimmune Connective Tissue Diseases. Dermatologic Clinics, 2018, 36, 267-275.	1.0	5
44	Current Treatment for Myositis. Current Treatment Options in Rheumatology, 2018, 4, 299-315.	0.6	36
46	Inhibition of Cyclic <scp>GMP</scp>â€<scp>AMP</scp> Synthase Using a Novel Antimalarial Drug Derivative in Trex1â€Deficient Mice. Arthritis and Rheumatology, 2018, 70, 1807-1819.	2.9	74
47	Antimalarials â€“ are they effective and safe in rheumatic diseases?. Reumatologia, 2018, 56, 164-173.	0.5	65
48	Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis. JAMA Dermatology, 2018, 154, 1199.	2.0	34
49	The Itchy Scalp. , 2019, , 219-228.		0
50	Adverse cutaneous drug reactions with antimalarials in cutaneous lupus and dermatomyositis: A retrospective cohort study. Journal of the American Academy of Dermatology, 2019, 81, 859-860.	0.6	12
51	Dermatomyositis: An Acute Flare and Current Treatments. Clinical Medicine Insights: Case Reports, 2019, 12, 117954761985537.	0.3	19
52	Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers. JAMA Dermatology, 2019, 155, 494.	2.0	21
53	Assessment of Antimalarial Therapy in Patients Who Are Hypersensitive to Hydroxychloroquine. JAMA Dermatology, 2019, 155, 491.	2.0	4
54	Integrated therapy decreases the mortality of patients with polymyositis and dermatomyositis: A Taiwan-wide population-based retrospective study. Journal of Ethnopharmacology, 2019, 236, 70-81.	2.0	1
55	Facing Uncertainty. New England Journal of Medicine, 2019, 381, 2253-2259.	13.9	3
56	Type <scp>IV</scp> allergy to antimalarials can mimic cutaneous manifestations of lupus erythematosus. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e94-e96.	1.3	3
57	Dermatomyositis: Diagnosis and treatment. Journal of the American Academy of Dermatology, 2020, 82, 283-296.	0.6	75
58	An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review. Journal of the American Academy of Dermatology, 2020, 82, 709-722.	0.6	21
59	Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations. European Journal of Pharmacology, 2020, 886, 173454.	1.7	14
60	Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CLpro. Frontiers in Molecular Biosciences, 2020, 7, 613401.	1.6	42
61	Appearance of skin rash in pediatric patients with <scp>COVID</scp> â€19: Three case presentations. Dermatologic Therapy, 2020, 33, e13594.	0.8	16

#	Article	IF	Citations
62	Hydroxychloroquine safety: A meta-analysis of randomized controlled trials. Travel Medicine and Infectious Disease, 2020, 36, 101812.	1.5	23
63	Dermatomyositis: An Update on Diagnosis and Treatment. American Journal of Clinical Dermatology, 2020, 21, 339-353.	3.3	54
64	Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review. Journal of the American Academy of Dermatology, 2020, 83, 563-578.	0.6	69
65	Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach. Journal of Biomolecular Structure and Dynamics, 2021, 39, 1-7.	2.0	271
66	Antimalarial Agents. , 2021, , 234-244.e4.		3
67	Analogue discovery of safer alternatives to HCQ and CQ drugs for SAR-CoV-2 by computational design. Computers in Biology and Medicine, 2021, 130, 104222.	3.9	12
68	Pruritus in autoimmune connective tissue diseases. Annals of Translational Medicine, 2021, 9, 441-441.	0.7	5
69	Cutaneous Vasculopathy in a COVID-19 Critically Ill Patient: A Histologic, Immunohistochemical, and Electron Microscopy Study. Case Reports in Critical Care, 2021, 2021, 1-6.	0.2	3
70	Hydroxychloroquine Induced DRESS (Drug Rash with Eosinophilia and Systemic Symptoms Syndrome) Mimicking SARS-COV-2 Illness: A Case Report with Review. Coronaviruses, 2021, 2, 521-526.	0.2	0
71	Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials. Scientific Reports, 2021, 11, 11974.	1.6	17
72	Computational study for identifying promising therapeutic agents of hydroxychloroquine analogues against SARSâ€CoVâ€2. Journal of Biomolecular Structure and Dynamics, 2022, 40, 11822-11836.	2.0	4
73	Exploring Dermatomyositis through an Interdisciplinary Lens: Pearls from Dermatology and Rheumatology. International Journal of Women's Dermatology, 2021, 7, 576-582.	1.1	0
74	Adverse cutaneous reactions secondary to hydroxychloroquine in patients with dermatomyositis, lupus erythematosus, and lichen planopilaris. Journal of the American Academy of Dermatology, 2021, 85, 1046-1047.	0.6	4
75	JUVENILE DERMATOMYOSITIS. , 2005, , 407-441.		15
76	Aminoquinoline antimalarial therapy in dermatomyositisâ€"are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?. Annals of Translational Medicine, 2018, 6, 154-154.	0.7	3
77	Chloroquine diphosphate: a risk factor for herpes zoster in patients with dermatomyositis/polymyositis. Clinics, 2013, 68, 621-627.	0.6	8
78	Chloroquine and hydroxychloroquine. , 2006, , 722-730.		1
79	Dermatological Manifestations of Dermatomyositis. , 2009, , 223-230.		0

#	Article	IF	Citations
80	ANTIPROTOZOAL AND ANTIHELMINTHIC DRUGS. , 2010, , 777-932.		1
84	Dermatitis Due to Systemic Disease. , 2012, , 95-103.		0
85	Collagen Vascular Diseases and Cutaneous Drug Reactions. , 2015, , 167-180.		0
86	Management Considerations: Refractory Skin Rash and Calcinosis. , 2020, , 299-314.		0
88	Hydroxychloroquine-induced erythroderma. Indian Journal of Pharmacology, 2017, 49, 132-134.	0.4	5
89	Hydroxychloroquine in Dermatology and Beyond: Recent Update. Indian Dermatology Online Journal, 2020, 11, 453-464.	0.2	10
90	Hydroxychloroquine in dermatology and beyond: Recent update. Indian Dermatology Online Journal, 2020, 11, 453.	0.2	25
92	3â€ƒThe lichenoid reaction pattern (â€˜interface dermatitisâ€™). , 2010, , 7-48.		0
93	Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM. Arthritis Research and Therapy, 2022, 24, 12.	1.6	9
98	Allergic Skin Rash Caused by Iguratimod: A Report of Two Cases. Cureus, 2022, , .	0.2	0
99	Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial. Journal of Investigative Dermatology, 2022, 142, 2651-2659.e1.	0.3	17
100	Antimalarial agents. , 2013, , 241-251.e3.		4
101	Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus. Frontiers in Medicine, 0, 9, .	1.2	10
102	Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases. Frontiers in Medicine, 0, 9, .	1.2	51
103	How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice. Internal Medicine Journal, 2023, 53, 311-317.	0.5	2
105	Dermatomyositis Diagnosis and Treatment in the Inpatient Setting. Current Dermatology Reports, 2023, 12, 56-68.	1.1	0